AngioDynamics (NSDQ:ANGO) said it plans to lay off up to 100 workers, or about 7.5% of its workforce, as it consolidates its footprint in upstate New York.
AngioDynamics
AngioDynamics wins CE Mark for AngioVac
AngioDynamics (NSDQ:ANGO) said it won CE Mark approval in the European Union for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit.
Report: Smith & Nephew chairman Buchanan to step down | Personnel Moves
AngioDynamics slowly getting the pieces into place
Legal: AngioDynamics settles distro spat with Cardinal Health
AngioDynamics (NSDQ:ANGO) closed the books on a 3-year-old distribution spat with Cardinal Health, with the companies agreeing to a terminate the lawsuit late last month.
AngioDynamics gains on Street-beating Q1 results, raised guidance
Shares of AngioDynamics (NSDQ:ANGO) are up today after the medical device company beat Wall Street’s earnings expectations with its fiscal 1st-quarter results.
AngioDynamics revisits sanctions against Biolitec
AngioDynamics lands Health Canada nod for Celerity system
AngioDynamics (NSDQ:ANGO) said its Canadian distribution partner won approval north of the border to market its Celerity tip location system for peripherally inserted central catheters.
AngioDynamics lands 510(k) for BioFlo Port
AngioDynamics (NSDQ:ANGO) roped in another FDA win for its BioFlo device, the 2nd clearance for a product line the medical device company picked up through its $372 million Navylist buyout.
AngioDynamics narrows losses, meets The Street in Q4
Albany, N.Y.-based AngioDynamics (NSDQ:ANGO) met Wall Street’s Q4 expectations, but didn’t gain much favor, with shares down 2.3% as of about 12:35 p.m. today.
AngioDynamics wins clearances in the U.S., Canada
AngioDynamics (NSDQ:ANGO) celebrated 2 regulatory wins this week, an FDA 510(k) clearance for its Xcela Plus Port family and a nod from Canadian regulators for its Smart Port Power-Injectable Ports.